The role of cholinergic balance perturbation in neurological diseases

Drug News and Perspectives

Volumn 20, Issue 7, 2007, Pages 421-429

  Nizri, Eran ^a   Wirguin, Itzhak ^b   Brenner, Talma ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA SERON; BETA1A INTERFERON; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; COMPLEMENTARY RNA; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; GLATIRAMER; IBUPROFEN; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; BRADYCARDIA; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); DIARRHEA; DISEASE COURSE; DRUG HALF LIFE; DRUG MEGADOSE; EATON LAMBERT SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MICTURITION; MULTIPLE SCLEROSIS; MUSCLE ACTION POTENTIAL; MUSCLE CRAMP; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NASAL DISCHARGE; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NERVOUS SYSTEM; REVIEW; SALIVATION DISORDER; SIDE EFFECT; SWEATING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HOMEOSTASIS; HUMANS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NERVOUS SYSTEM DISEASES;

EID: 36849093040     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.7.1149629     Document Type: Review

References (64)

1. Grisaru, D., Sternfeld, M., Eldor, A., Glick, D. and Soreq, H. Structural roles of acetyl cholinesterase variants in biology and pathology. Eur J Biochem 1999, 264(3): 672-86.
2. Conti-Fine, B.M., Milani, M. and Kaminski, H.J. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116(11): 2843-54.
3. Desai, A.K. and Grossberg, G.T. Diagnosis and treatment of Alzheimer's disease. Neurology 2005, 64(12 Suppl. 3): S34-9.
4. Argov, Z. and Wirguin, I. Drugs and the neuromuscular junction: Pharmacotherapy and adverse effects in transmission disorders. In: RP L (Ed.). Handbook of myasthenia gravis. New York, Marcel Dekker, Inc, 1994. 295-319.
5. Kawashima, K. and Fujii, T. The lymphocytic cholinergic system and its biological function. Life Sci 2003, 72(18-19): 2101-9.
6. Borovikova, L.V., Ivanova, S., Zhang, M. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405(6785): 458-62.
7. Wang, H., Yu, M., Ochani, M. et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421(6921): 384-8.
8. Barnes, P.J. and Karin, M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336(15): 1066-71.
9. Nizri, E., Hamra-Amitay, Y., Sicsic, C., Lavon, I. and Brenner, T. Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacol 2006, 50(5): 540-7.
10. Fujii, T. and Kawashima, K. YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells. Gen Pharmacol 2000, 35(2): 71-5.
11. Calabresi, P., Picconi, B., Parnetti, L. and Di Filippo, M. A convergent model for cognitive dysfunctions in Parkinson's disease: The critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006, 5(11): 974-83.
12. Cragg, S.J. Meaningful silences: How dopamine listens to the ACh pause. Trends Neurosci 2006, 29(3): 125-31.
13. Drachman, D.B. Myasthenia gravis. N Engl J Med 1994, 330(25): 1797-810.
14. Newsom-Davis, J. Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 2004, 160(2): 177-80.
15. Guidelines in electrodiagnostic medicine. American Association of Electrodiagnostic Medicine. Muscle Nerve 1992, 15(2): 229-53.
16. Brenner, T., Hamra-Amitay, Y., Evron, T., Boneva, N., Seidman, S. and Soreq, H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. Faseb J 2003, 17(2): 214-22.
17. Anderson, N.E., Hutchinson, D.O., Nicholson, G.J., Aitcheson, F. and Nixon, J.M. Intestinal pseudo-obstruction, myasthenia gravis, and thymoma. Neurol 1996, 47(4): 985-7.
18. Pande, R. and Leis, A.A. Myasthenia gravis, thymoma, intestinal pseudo-obstruction, and neuronal nicotinic acetylcholine receptor antibody. Muscle Nerve 1999, 22(11): 1600-2.
19. Vernino, S., Low, P.A., Fealey, R.D., Stewart, J.D., Farrugia, G. and Lennon, V.A. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000, 343(12): 847-55.
20. Lennon, V.A., Ermilov, L.G., Szurszewski, J.H. and Vernino, S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003, 111(6): 907-13.
21. Nussbaum, R.L. and Ellis, C.E. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003, 348(14): 1356-64.
22. Monsonego, A. and Weiner, H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 2003, 302(5646): 834-8.
23. Cummings, J.L. Alzheimer's disease. N Engl J Med 2004, 351(1): 56-67.
24. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006(1): CD005593.
25. Kaduszkiewicz, H., Zimmermann, T., BeckBornholdt, H.P. and van den Bussche, H. Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. Bmj 2005, 331(7512): 321-7.
26. Raskind, M.A., Peskind, E.R., Wessel, T. and Yuan, W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000, 54(12): 2261-8.
27. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R. and Friedhoff, L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998, 50(1): 136-45.
28. Giacobini, E. Cholinesterases: New roles in brain function and in Alzheimer's disease. Neurochem Res 2003, 28(3-4): 515-22.
29. Nitsch, R.M., Slack, B.E., Wurtman, R.J. and Growdon, J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258(5080): 304-7.
30. Hock, C., Maddalena, A., Raschig, A. et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003, 10(1): 1-6.
31. Inestrosa, N.C., Alvarez, A., Godoy, J., Reyes, A. and De Ferrari, G.V. Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 2000, 176: 53-9.
32. Inestrosa, N.C., Alvarez, A., Dinamarca, M.C., Perez-Acle, T. and Colombres, M. Acetylcholinesterase-amyloid-beta-peptide interaction: Effect of Congo Red and the role of the Wnt pathway. Curr Alzheimer Res 2005, 2(3): 301-6.
33. Nizri, E., Irony-Tur-Sinai, M., Grigoriadis, N., Abramsky, O., Amitai, G. and Brenner, T. Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development. Pharmacol 2007, 79(1): 42-9.
34. Pollak, Y., Gilboa, A., Ben-Menachem, O., Ben-Hur, T., Soreq, H. and Yirmiya, R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol 2005, 57(5): 741-5.
35. Monsonego, A., Zota, V., Karni, A. et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003, 112(3): 415-22.
36. Shytle, R.D., Mori, T., Townsend, K. et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004, 89(2): 337-43.
37. De Simone, R., Ajmone-Cat, M.A., Carnevale, D. and Minghetti, L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2005, 2(1): 4.
38. Teaktong, T., Graham, A., Court, J. et al. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 2003, 41(2): 207-11.
39. Reale, M., Iarlori, C., Gambi, F., Feliciani, C., Isabella, L. and Gambi, D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacol 2006, 50(5): 606-13.
40. Reale, M., Iarlori, C., Gambi, F. et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 2004, 148(1-2): 162-71.
41. Tabet, N. Acetylcholinesterase inhibitors for Alzheimer's disease: Anti-inflammatories in acetylcholine clothing! Age Ageing 2006, 35(4): 336-8.
42. Bard, F., Cannon, C., Barbour, R. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6(8): 916-9.
43. Schenk, D., Barbour, R., Dunn, W. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740): 173-7.
44. Wyss-Coray, T., Yan, F., Lin, A.H., Lambris, J.D., Alexander, J.J., Quigg, R.J. and Masliah, E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A 2002, 99(16): 10837-42.
45. Akiyama, H., Barger, S., Barnum, S. et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21(3): 383-421.
46. Wyss-Coray, T. and Mucke, L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35(3): 419-32.
47. Scharf, S., Mander, A., Ugoni, A., Vajda, F. and Christophidis, N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurol 1999, 53(1): 197-201.
48. Aisen, P.S., Schafer, K.A., Grundman, M. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. Jama 2003, 289(21): 2819-26.
49. Aisen, P.S., Davis, K.L., Berg, J.D. et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54(3): 588v93.
50. Hemmer, B., Archelos, J.J. and Hartung, H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002, 3(4): 291-301.
51. Steinman, L. Multiple sclerosis: A two-stage disease. Nat Immunol 2001, 2(9): 762-4.
52. Bjartmar, C., Wujek, J.R. and Trapp, B.D. Axonal loss in the pathology of MS: Consequences for understanding the progressive phase of the disease. J Neurol Sci 2003, 206(2): 165-71.
53. Kesselring, J. and Beer, S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005, 4(10): 643-52.
54. Murray, TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006, 332(7540): 525-7.
55. Chaudhuri, A. Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ 2006, 332(7538): 416-9.
56. Rizvi, S.A. and Agius, M.A. Current approved options for treating patients with multiple sclerosis. Neurol 2004, 63(12 Suppl. 6): S8-14.
57. Steinman, L. and Zamvil, S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006, 60(1): 12-21.
58. Nizri, E., Adani, R., Meshulam, H., Amitai, G. and Brenner, T. Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments. Neurosci Lett 2005, 376(1): 46-50.
59. Bagert, B., Camplair, P. and Bourdette, D. Cognitive dysfunction in multiple sclerosis: Natural history, pathophysiology and management. CNS Drugs 2002, 16(7): 445-55.
60. Gilchrist, A.C. and Creed, F.H. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res 1994, 38(3): 193-201.
61. Amato, M.P., Portaccio, E. and Zipoli, V. Are there protective treatments for cognitive decline in MS? J Neurol Sci 2006, 245(1-2): 183-6.
62. Pliskin, N.H., Hamer, D.P., Goldstein, D.S., Towle, V.L., Reder, A.T., Noronha, A. and Arnason, B.G. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurol 1996, 47(6): 1463-8.
63. Krupp, L.B., Christodoulou, C., Melville, P., Schert, W.F., MacAllister, W.S. and Elkins, L.E. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurol 2004, 63(9): 1579-85.
64. D'Intino, G., Paradisi, M., Fernandez, M., Giuliani, A., Aloe, L., Giardino, L. and Calza, L. Cognitive deficit associated with cholinergic and nerve growth factor downregulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A 2005, 102(8): 3070-5.